Syncom Formulations (India) Limited (NSE:SYNCOMF)
19.96
-0.05 (-0.25%)
Sep 24, 2026, 3:29 PM IST
NSE:SYNCOMF Revenue
Syncom Formulations (India) had revenue of 1.26B INR in the quarter ending June 30, 2026, with 7.38% growth. This brings the company's revenue in the last twelve months to 4.98B, up 0.63% year-over-year. In the fiscal year ending March 31, 2026, Syncom Formulations (India) had annual revenue of 4.89B with 5.20% growth.
Revenue (ttm)
4.98B
Revenue Growth
+0.63%
P/S Ratio
3.79
Revenue / Employee
5.52M
Employees
902
Market Cap
18.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.89B | 241.59M | 5.20% |
| Mar 31, 2025 | 4.65B | 2.02B | 76.55% |
| Mar 31, 2024 | 2.63B | 391.33M | 17.45% |
| Mar 31, 2023 | 2.24B | 45.91M | 2.09% |
| Mar 31, 2022 | 2.20B | -251.42M | -10.27% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.73B |
| Solara Active Pharma Sciences | 14.31B |
| Windlas Biotech | 9.42B |
| Ind-Swift Laboratories | 6.74B |
| Sigachi Industries | 4.71B |
| Beta Drugs | 4.10B |
| Jagsonpal Pharmaceuticals | 2.94B |
| Amanta Healthcare | 2.91B |